G01N 2333/475
Assays involving growth factors
G01N2333/475 (Assays involving growth factors) appears on 977 US grants and 1,811 published applications in this corpus.
Search patents in G01N- Granted patents
- 977
- Published applications
- 1,811
- Assignees
- 853
- Inventors
- 3,497
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 8 | 0 |
| 1994 | 0 | 0 |
| 1995 | 9 | 0 |
| 1996 | 9 | 0 |
| 1997 | 26 | 0 |
| 1998 | 43 | 0 |
| 1999 | 17 | 0 |
| 2000 | 18 | 0 |
| 2001 | 14 | 5 |
| 2002 | 23 | 40 |
| 2003 | 15 | 108 |
| 2004 | 25 | 54 |
| 2005 | 20 | 68 |
| 2006 | 23 | 65 |
| 2007 | 24 | 58 |
| 2008 | 23 | 69 |
| 2009 | 41 | 79 |
| 2010 | 40 | 96 |
| 2011 | 49 | 87 |
| 2012 | 35 | 68 |
| 2013 | 37 | 96 |
| 2014 | 41 | 94 |
| 2015 | 45 | 123 |
| 2016 | 49 | 92 |
| 2017 | 41 | 88 |
| 2018 | 42 | 79 |
| 2019 | 38 | 51 |
| 2020 | 51 | 68 |
| 2021 | 35 | 62 |
| 2022 | 32 | 48 |
| 2023 | 24 | 61 |
| 2024 | 26 | 56 |
| 2025 | 24 | 56 |
| 2026 | 24 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- G01N 2333/495Transforming growth factor [tgf]Indexing code182
- G01N 2333/50Fibroblast growth factors [fgf]Indexing code167
- G01N 2333/485Epidermal growth factor [egf]Indexing code142
- G01N 2333/515Angiogenesic factorsIndexing code107
- G01N 2333/51Bone morphogenetic factorIndexing code70
- G01N 2333/49Platelet-derived growth factor [pdgf]Indexing code52
- G01N 2333/4756Neuregulins, i.e. p185erbb2 ligands, glial growth factor, heregulin, aria, neu differentiation factorIndexing code40
- G01N 2333/48Nerve growth factor [ngf]Indexing code34
All 10 subgroupsShow fewer
Recent patents
- Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)11 Aug 2026US 12,702,710 B2Medicenna Therapeutics Inc.
- Biological markers in the diagnosis of endometriosis4 Aug 2026US 12,699,103 B2Yeditepe Universitesi
- Method for treating SARS-COV-2 infectious disease28 Jul 2026US 12,692,300 B2Research & Business Foundation Sungkyunkwan University
- Magnetic point-of-care systems and assays for determining GFAP in biological samples30 Jun 2026US 12,669,513 B2Abbott Laboratories
- Measurement of bevacizumab-insensitive vascular endothelial growth factor-a16 Jun 2026US 12,656,349 B2Board of Regents, The University of Texas System
- Magnetic point-of-care systems and assays for determining gfap in biological samples8 Oct 2026US 2026/0309722 A1Abbott Laboratories
- Human anti-fgf2 monoclonal antibody (mab), pharmaceutical composition comprising same, use thereof and kit for the detection of cancer in a biological sample comprising said mab1 Oct 2026US 2026/0297170 A1Instituto Butantan
- Anti-vegfa antibody or antigen-binding fragment thereof and use thereof24 Sep 2026US 2026/0285961 A1Quaerite Biopharm Research (Beijing) Co., Ltd.
- Biomarkers for neurodegenerative disease17 Sep 2026US 2026/0272976 A1Neuvivo, Inc.
- Dll1 marker panels for early detection of sepsis3 Sep 2026US 2026/0259226 A1Roche Diagnostics Operations, Inc.
Most cited
By later US patents
- Nucleic acid ligands561US 5,475,096 AUniversity Research Corporation · 1995
- Systematic evolution of ligands by exponential enrichment: chimeric selex281US 5,637,459 ANeXstar Pharmaceuticals, Inc. · 1997
- High affinity nucleic acid ligands containing modified nucleotides228US 5,660,985 ANeXstar Pharmaceuticals, Inc. · 1997
- Methods of producing nucleic acid ligands204US 5,595,877 ANeXstar Pharmaceuticals, Inc. · 1997
- High affinity nucleic acid ligands containing modified nucleotides190US 5,958,691 ANeXstar Pharmaceuticals, Inc. · 1999